Hypoxia and inflammation are closely linked at the molecular, cellular, and clinical levels. Hypoxia induces inflammation through mechanisms involving oxygen-sensing prolyl hydroxylases (PHDs) and hypoxia-inducible factors (HIFs). HIFs regulate gene expression in response to hypoxia, influencing inflammatory processes. Hypoxia can trigger the release of proinflammatory cytokines and increase vascular leakage, as seen in high-altitude sickness and inflammatory bowel disease. Inflammation can also lead to tissue hypoxia, as observed in inflamed intestinal tissues and certain cancers. HIFs play a key role in both hypoxia and inflammation. They are involved in the regulation of immune responses, including the activation of innate and adaptive immune systems. HIF-1α is essential for myeloid cell function in hypoxic conditions, and its deficiency can impair bacterial clearance. HIF also influences adaptive immunity by modulating T-cell function and regulatory T-cell activity. In cancer, hypoxia is a common feature of solid tumors, and HIFs contribute to tumor growth, angiogenesis, and metastasis. Hypoxia can also enhance the survival of cancer cells by promoting the expression of genes involved in cell survival and proliferation. Targeting HIF pathways may offer new therapeutic strategies for cancer treatment. Infections can also lead to hypoxia and inflammation, with pathogens exploiting the host's HIF pathway for their own benefit. Hypoxia can enhance the survival of pathogens by stabilizing HIF and promoting the expression of genes involved in angiogenesis and immune evasion. Overall, hypoxia and inflammation are interdependent processes that influence a wide range of diseases, including inflammatory bowel disease, cancer, and infections. Understanding the molecular mechanisms underlying this interaction may lead to new therapeutic approaches for these conditions.Hypoxia and inflammation are closely linked at the molecular, cellular, and clinical levels. Hypoxia induces inflammation through mechanisms involving oxygen-sensing prolyl hydroxylases (PHDs) and hypoxia-inducible factors (HIFs). HIFs regulate gene expression in response to hypoxia, influencing inflammatory processes. Hypoxia can trigger the release of proinflammatory cytokines and increase vascular leakage, as seen in high-altitude sickness and inflammatory bowel disease. Inflammation can also lead to tissue hypoxia, as observed in inflamed intestinal tissues and certain cancers. HIFs play a key role in both hypoxia and inflammation. They are involved in the regulation of immune responses, including the activation of innate and adaptive immune systems. HIF-1α is essential for myeloid cell function in hypoxic conditions, and its deficiency can impair bacterial clearance. HIF also influences adaptive immunity by modulating T-cell function and regulatory T-cell activity. In cancer, hypoxia is a common feature of solid tumors, and HIFs contribute to tumor growth, angiogenesis, and metastasis. Hypoxia can also enhance the survival of cancer cells by promoting the expression of genes involved in cell survival and proliferation. Targeting HIF pathways may offer new therapeutic strategies for cancer treatment. Infections can also lead to hypoxia and inflammation, with pathogens exploiting the host's HIF pathway for their own benefit. Hypoxia can enhance the survival of pathogens by stabilizing HIF and promoting the expression of genes involved in angiogenesis and immune evasion. Overall, hypoxia and inflammation are interdependent processes that influence a wide range of diseases, including inflammatory bowel disease, cancer, and infections. Understanding the molecular mechanisms underlying this interaction may lead to new therapeutic approaches for these conditions.